NCT01959412 - Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Asthma

Interventions

DRUG

Indacaterol 27.5 mcg

indacaterol 27.5 mcg twice daily inhaled once via inhaler

DRUG

Indacaterol 37.5

Indacaterol 37.5 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 55 mcg

Indacaterol 55 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 75 mcg

Indacaterol 75 mcg once daily, inhaled once via inhaler

DRUG

Indacaterol 150 mcg

Indacaterol 150 mcg once daily, inhaled once via inhaler

DRUG

Placebo

Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher

Trial Locations (12)

27607

Novartis Investigative Site, Raleigh

63141

Novartis Investigative Site, St Louis

75231

Novartis Investigative Site, Dallas

79902

Novartis Investigative Site, El Paso

80112

Novartis Investigative Site, Centennial

90048

Novartis Investigative Site, Los Angeles

92647

Novartis Investigative Site, Huntington Beach

92691

Novartis Investigative Site, Mission Viejo

97213

Novartis Investigative Site, Portland

02747

Novartis Investigative Site, North Dartmouth

08558

Novartis Investigative Site, Skillman

97504-8741

Novartis Investigative Site, Medford